Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer

This study tests whether combining amplitude-modulated radiofrequency electromagnetic fields (a low-level energy treatment) with two chemotherapy drugs — TAS-102 (lonsurf) and bevacizumab — can help people with colorectal cancer that has spread to the liver and no longer responds to standard chemotherapy. **You may be eligible if...** - You are 18 or older - You have confirmed colorectal cancer with liver metastases (cancer spread to the liver) - You have already received at least two standard chemotherapy regimens that have stopped working - You have good physical function (ECOG 0-1) **You may NOT be eligible if...** - Your colorectal cancer has not spread to the liver - You have not yet tried at least two prior standard chemotherapy regimens - Your overall health is too poor to tolerate additional treatment Talk to your doctor to see if this trial is right for you.